Clinical Benefit‐Risk Assessment of Nivolumab 240 mg Every 2 Weeks in Chinese Patients With Advanced and Metastatic Solid Tumors

Nivolumab 240 mg every 2 weeks is approved in China by the National Medical Product Agency for squamous cell carcinoma of the head and neck and gastric cancer, based on population pharmacokinetic (PPK) analyses and benefit‐risk assessment of safety/efficacy in solid tumors, including Chinese and glo...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheng, Jennifer, Zhang, Jason, Baudelet, Christine, Roy, Amit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Pharmacometrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359491/
https://www.ncbi.nlm.nih.gov/pubmed/33501654
http://dx.doi.org/10.1002/jcph.1821

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359491/
https://www.ncbi.nlm.nih.gov/pubmed/33501654
http://dx.doi.org/10.1002/jcph.1821

Ejemplares similares